Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, Ellume Get FDA Emergency Use Authorizations for SARS-CoV-2 Tests

The story previously incorrectly stated Ellume's test is a serology test. Also, the HHS contract was to scale up production of a test, not to develop it. 

NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations for an RT-PCR-based SARS-CoV-2 test developed by Thermo Fisher Scientific and a point-of-care antigen test for the virus from Ellume.

Thermo Fisher's TaqPath COVID-19 RNase P Combo Kit 2.0 is designed to detect SARS-CoV-2 nucleic acid in healthcare provider-collected nasopharyngeal swabs and anterior or mid-turbinate nasal swabs from individuals suspected of having COVID-19. It is also authorized for use in asymptomatic individuals when tested twice over two or three days with at least 24 hours, and no more than 36 hours, between tests.

The test may be used by any lab CLIA-certified to perform high-complexity tests, the FDA said.

In June, Waltham, Massachusetts-based Thermo Fisher received FDA EUA for its TaqPath COVID-19 Pooling Kit, which tests for SARS-CoV-2 in up to five individual samples at once.

The Ellume Lab COVID Antigen Test is designed for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in direct mid-turbinate nasal swab specimens collected by healthcare providers.

The fluorescent lateral flow immunoassay may be used by any lab CLIA-certified to perform moderate-complexity, high-complexity, or waived tests, according to the FDA. It may also be used in point-of-care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

In February, Australia-based Ellume received a $231.8 million contract from the US Department of Health to increase production of an over-the-counter, at-home SARS-CoV-2 test.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.